What is Amicus Therapeutics?
Amicus Therapeutics operates as a patient-dedicated biotechnology enterprise, specializing in the discovery, development, and delivery of novel, high-quality medicines. The company maintains a rigorous focus on addressing the unmet needs of individuals living with rare metabolic diseases. Through a combination of proprietary research platforms and strategic clinical development, Amicus has established a robust pipeline designed to transform the standard of care for patients globally. Its market position is defined by a unique synthesis of scientific innovation and a patient-centric business model, allowing it to navigate the complexities of the rare disease landscape with precision and clinical efficacy.
How much funding has Amicus Therapeutics raised?
Amicus Therapeutics has raised a total of $475M across 2 funding rounds:
Stock Offering
$75M
Debt
$400M
Stock Issuance/Offering (2007): $75M, investors not publicly disclosed
Debt (2020): $400M led by Hayfin Capital Management LLP
Key Investors in Amicus Therapeutics
Hayfin Capital Management LLP
A leading alternative asset management firm that provides bespoke financing solutions to support the growth and operational requirements of established companies.
Undisclosed Investor
An institutional participant providing capital to support the long-term strategic objectives of the biotechnology firm.
Undisclosed Investor
A strategic partner contributing to the financial foundation of the company's research and development initiatives.
What's next for Amicus Therapeutics?
With the recent influx of capital, Amicus Therapeutics is well-positioned to accelerate its late-stage clinical programs and expand its commercial footprint. The strategic deployment of these funds will likely prioritize the scaling of manufacturing capabilities and the global distribution of its therapeutic portfolio. As the company moves into its next phase of enterprise-level growth, stakeholders will be monitoring the progression of its pipeline and the potential for further market penetration in key international territories. The focus remains on maintaining a sustainable growth trajectory while continuing to deliver breakthrough treatments to underserved patient populations.
See full Amicus Therapeutics company page
